SynthesisMedical oncology (Northwood, London, England)2015
Treatment on advanced NSCLC: platinum-based chemotherapy plus erlotinib or platinum-based chemotherapy alone? A systematic review and meta-analysis of randomised controlled trials.
Synthesis in Medical oncology (Northwood, London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 9 syntheses or guidelines pooled it.
- Circular RNAs as Prognostic Biomarkers in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.Frontiers in genetics · 2022Pooled it
- High-intensity statin therapy yields better outcomes in acute coronary syndrome patients: a meta-analysis involving 26,497 patients.Lipids in health and disease · 2020Pooled it
- Pooled it
- Do histological variants in urothelial carcinoma of the bladder portend poor prognosis? A systematic review and meta-analysis.Oncotarget · 2017Pooled it
- The role of neoadjuvant chemotherapy for resectable colorectal liver metastases: a systematic review and meta-analysis.Oncotarget · 2016Pooled it
- Pooled it
- Pooled it
- Coffee consumption and risk of endometrial cancer: a dose-response meta-analysis of prospective cohort studies.Scientific reports · 2015Pooled it
- Chemotherapy plus Erlotinib versus Chemotherapy Alone for Treating Advanced Non-Small Cell Lung Cancer: A Meta-Analysis.PloS one · 2015Pooled it
- Total flavonoids suppress lung cancer growth via the COX-2-mediated Wnt/β-catenin signaling pathway.Oncology letters · 2020Article
- Ultrasonic diagnosis combined with targeted ultrasound contrast agent improves diagnostic sensitivity of ultrasonic for non-small cell lung cancer patients.Experimental and therapeutic medicine · 2018Article
- Effect of Intermittent versus Chronic Calorie Restriction on Tumor Incidence: A Systematic Review and Meta-Analysis of Animal Studies.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We performed a systematic review and meta-analysis to assess the potential of erlotinib plus platinum-based chemotherapy relative to platinum-based chemotherapy alone for advanced non-small-cell lung cancer (NSCLC). Search of PubMed, EMBASE, Web of Science, CBM, CNKI, China Wan Fang databases and the Cochrane library was performed for studies regarding erlotinib plus platinum-based chemotherapy for advanced NSCLC published between 1 January 2000 and 28 August 2014. We identified eight eligible studies including 3,363 patients with advanced NSCLC. For PFS measure, an HR of 0.73 (0.58-0.93) with statistical significance was estimated when erlotinib plus platinum-based chemotherapy compared with platinum-based chemotherapy alone; objective response rate of 32.86 versus 24.85 % was obtained for both groups, respectively. HR of 0.93 (0.86-1.00) with P of 0.170 was calculated for OS. We concluded that the erlotinib plus chemotherapy for advanced NSCLC could increase PFS and objective response rate, but not benefit OS.
Indexed as
Identifiers
25579169What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.